Program 3 (Nkarta Therapeutics)

N/A

Report date: 2025/01/26 15:40:06

Base Information

Drug NameProgram 3 (Nkarta Therapeutics)

Drug Alias Nameallogeneic CAR NK-cell therapy (Nkarta Therapeutics)allogeneic CAR NK cell therapy (Nkarta)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNatural killer cells stimulantsImmunostimulants

TargetsUpdating

Therapy Area/IndicationsSolid tumoursHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNkarta Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesNkarta Therapeutics

Inactive CompaniesN/A

Active IndicationsSolid tumoursHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A